Sugi Predict

Sugi Predict / Compounds / SCHEMBL363351

SCHEMBL363351

SCHEMBL363351

O=C(NC1CC1)c1ccccc1F

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.60
▸ ALDH1A1 P00352 3/20 0.56
▸ POLB P06746 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ ALOX12 P18054 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ GAA P10253 2/20 0.56
▸ HPGD P15428 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ P2RX7 Q99572 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ GRM5 P41594 1/20 0.56
▸ MCHR1 Q99705 1/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ CCR3 P51677 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23462319 0.93 NPC1 (0.55) NPC1ALDH1A1POLBMAPTALOX12
SCHEMBL23462320 0.93 NPC1 (0.55) NPC1ALDH1A1POLBMAPTALOX12
SCHEMBL28465600 0.93 NPC1 (0.66) NPC1ALDH1A1MAPTSMN1; SMN2NPSR1
SCHEMBL10278648 0.93 GRM5 (0.64) NPC1ALDH1A1POLBMAPTALOX12
SCHEMBL12181533 0.91 NPC1 (0.69) NPC1ALDH1A1MAPTSMN1; SMN2NPSR1
SCHEMBL3455151 0.91 NPC1 (0.69) NPC1ALDH1A1MAPTSMN1; SMN2NPSR1
SCHEMBL2104212 0.90 NPC1 (0.55) NPC1ALDH1A1POLBMAPTALOX12
SCHEMBL14938627 0.89 NPC1 (0.54) NPC1ALDH1A1POLBMAPTALOX12
SCHEMBL30572200 0.89 NPC1 (0.54) NPC1ALDH1A1POLBMAPTALOX12
SCHEMBL24267995 0.88 GAA (0.56) NPC1ALDH1A1POLBMAPTALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3280795-A1 COMBINATION OF CHIMERIC ANTIGEN RECEPTOR THERAPY AND AMINO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2018-02-14 — — EP claimed
CN-105431436-B Pyrrolo [2,3-D ] pyrimidine derivatives, processes for their preparation and their use as kinase inhibitors 内尔维阿诺医学科学有限公司 2017-11-28 — — CN claimed
WO-2016164580-A1 COMBINATION OF CHIMERIC ANTIGEN RECEPTOR THERAPY AND AMINO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2016-10-13 — — WO claimed
US-8163771-B2 11 β-HSD1 modulators EXELIXIS, INC. (US) 2012-04-24 — — US claimed
EP-1501830-B1 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-05 — — EP claimed
EP-2280966-A1 AZABICYCLO [3.2.1]OCTYL DERIVATIVES AS 11 BETA-HSD1 MODULATORS Exelixis, Inc. (US) 2011-02-09 — — EP claimed
US-20100105675-A2 11 BETA-HSD1 MODULATORS EXELIXIS, INC. (US) 2010-04-29 — — US claimed
US-20090247515-A1 11 Beta-HSD1 Modulators EXELIXIS, INC. (US) 2009-10-01 — — US claimed
WO-2009114173-A1 AZABICYCLO [3. 2. I] OCTYL DERIVATIVES AS 11 BETA-HSDL MODULATORS EXELIXIS, INC. (US) 2009-09-17 — — WO claimed
EP-1620403-B1 NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2007-11-28 — — EP claimed
US-20260069605-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-03-12 — — US disclosed
US-20250295655-A1 BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION Alk-Abelló A/S (DK) 2025-09-25 — — US disclosed
EP-4310084-A1 PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF Jinan University (CN) 2024-01-24 — — EP disclosed
US-20230382900-A1 INHIBITORS OF BTK NEWAVE PHARMACEUTICAL INC. 2023-11-30 — — US disclosed
EP-3491016-A1 COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS Novartis AG (CH) 2019-06-05 — — EP disclosed
US-20100105675-A2 11 BETA-HSD1 MODULATORS EXELIXIS, INC. (US) 2010-04-29 — — US disclosed
US-20090247515-A1 11 Beta-HSD1 Modulators EXELIXIS, INC. (US) 2009-10-01 — — US disclosed
WO-2009114173-A1 AZABICYCLO [3. 2. I] OCTYL DERIVATIVES AS 11 BETA-HSDL MODULATORS EXELIXIS, INC. (US) 2009-09-17 — — WO disclosed
EP-1957495-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-08-20 — — EP disclosed
WO-2007064045-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105675-A2 11 BETA-HSD1 MODULATORS HSD11B1, HSD11B2, HSD3B1 NPC1 714/4885ALDH1A1 53/4885POLB 2249/4885
US-20230382900-A1 INHIBITORS OF BTK BTK, SYK, LYN NPC1 3784/4885ALDH1A1 3388/4885POLB 3072/4885
US-20090247515-A1 11 Beta-HSD1 Modulators HSD11B1, HSD11B2, HSD3B1 NPC1 734/4885ALDH1A1 68/4885POLB 2040/4885
US-20250295655-A1 BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION BTK, SYK, ABL1 NPC1 3643/4885ALDH1A1 4690/4885POLB 4035/4885
US-20260069605-A1 KRAS INHIBITORS KRAS, NRAS, HRAS NPC1 286/4885ALDH1A1 966/4885POLB 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.